- Home
- RPTX vs APLT Comparison
RPTX vs APLT Comparison
Compare RPTX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPTX
- APLT
- Stock Information
- Founded
- RPTX 2016
- APLT 2016
- Country
- RPTX Canada
- APLT United States
- Employees
- RPTX N/A
- APLT N/A
- Industry
- RPTX Biotechnology: Pharmaceutical Preparations
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- RPTX Health Care
- APLT Health Care
- Exchange
- RPTX Nasdaq
- APLT Nasdaq
- Market Cap
- RPTX 141.1M
- APLT 128.0M
- IPO Year
- RPTX 2020
- APLT 2019
- Fundamental
- Price
- RPTX $1.32
- APLT $0.88
- Analyst Decision
- RPTX Strong Buy
- APLT Buy
- Analyst Count
- RPTX 3
- APLT 6
- Target Price
- RPTX $7.00
- APLT $6.10
- AVG Volume (30 Days)
- RPTX 709.5K
- APLT 12.1M
- Earning Date
- RPTX 11-07-2024
- APLT 11-07-2024
- Dividend Yield
- RPTX N/A
- APLT N/A
- EPS Growth
- RPTX N/A
- APLT N/A
- EPS
- RPTX N/A
- APLT N/A
- Revenue
- RPTX $66,524,000.00
- APLT N/A
- Revenue This Year
- RPTX $13.22
- APLT N/A
- Revenue Next Year
- RPTX N/A
- APLT $2,664.24
- P/E Ratio
- RPTX N/A
- APLT N/A
- Revenue Growth
- RPTX 18.19
- APLT N/A
- 52 Week Low
- RPTX $1.23
- APLT $0.84
- 52 Week High
- RPTX $8.49
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- RPTX 30.27
- APLT 16.80
- Support Level
- RPTX $1.23
- APLT $0.95
- Resistance Level
- RPTX $4.07
- APLT $1.14
- Average True Range (ATR)
- RPTX 0.34
- APLT 0.16
- MACD
- RPTX -0.20
- APLT 0.05
- Stochastic Oscillator
- RPTX 3.34
- APLT 4.60
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.